Edwards Lifesciences closes Valtech Cardio acquisition
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Edwards Lifesciences Corp. completed the acquisition of Israel-based Valtech Cardio Ltd. for $340 million in stock and cash.
In addition, the deal provides for the potential of up to $350 million in prespecified milestone-driven payments over the next 10 years.
Valtech is the developer of the cardioband system for transcatheter repair of the mitral and tricuspid valves.
